- The situation at Star Scientific (STSI +0.9%) is bleak, according to SA contributor Paulo Santos.
- He thinks the company's desperate measure to raise capital through the issuance of new shares is just buying time with hopes for a revenue bonanza fading.
- The bull case on STSI hinges on the potential for Anatabloc to be a mass market product. The company expects a patent related to the treatment's active ingredient to be granted shortly.
From other sites
at MarketWatch.com (Nov 12, 2012)
at Fox Business (Aug 27, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs